J Kulisevsky

Summary

Publications

  1. pmc Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Spain
    PLoS ONE 8:e54980. 2013
  2. pmc Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy
    Merce Martínez-Corral
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Sant Pau Institute of Biomedical Research IIB Sant Pau, Autonomous University of Barcelona and Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas CIBERNED, Sant Antoni M Claret 167, 08025 Barcelona, Spain
    Parkinsons Dis 2010:930627. 2010
  3. doi request reprint Advanced Parkinson's disease: clinical characteristics and treatment. Part II
    J Kulisevsky
    Servicio de Neurologia, Hospital Sant Pau, Barcelona, España Electronic address
    Neurologia 28:558-83. 2013
  4. ncbi request reprint [Advanced Parkinson's disease: clinical characteristics and treatment (part 1)]
    J Kulisevsky
    Servicio de Neurologia, Hospital Sant Pau, IIB Sant Pau, CIBERNED, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Neurologia 28:503-21. 2013
  5. doi request reprint Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Spain
    Parkinsonism Relat Disord 19:812-7. 2013
  6. doi request reprint Evaluation of doctor/patient satisfaction with the use of the Parkinson's Disease Dementia-Short-Screen (PDD-SS): a screening test for dementia in Parkinson's disease (DIFFUSION study)
    J Kulisevsky
    Unidad de Trastornos del Movimiento, Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Espana
    Neurologia 26:461-7. 2011
  7. doi request reprint Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Institute of Biomedical Research Barcelona, Spain
    Eur Neurol 67:4-11. 2012
  8. doi request reprint Motor changes during sertraline treatment in depressed patients with Parkinson's disease*
    J Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Eur J Neurol 15:953-9. 2008
  9. ncbi request reprint Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, Barcelona, Spain
    Mov Disord 24:1103-10. 2009
  10. ncbi request reprint Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model
    M Casas
    Departament de Psiquiatria, Institut de Recerca Sant Pau, Programa Sant Pau CITRAN y FISP, Universitat Autonoma de Barcelona, Unitat de Toxicomanies, Hospital de la Sta Creu i St Pau, Barcelona, Spain
    Eur Neuropsychopharmacol 9:515-21. 1999

Collaborators

Detail Information

Publications60

  1. pmc Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Spain
    PLoS ONE 8:e54980. 2013
    ..Mild cognitive impairment in PD (PD-MCI) seems to represent a transitional state between PD-NC and PDD. Few studies have explored the structural changes that differentiate PD-NC from PD-MCI and PDD patients...
  2. pmc Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy
    Merce Martínez-Corral
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Sant Pau Institute of Biomedical Research IIB Sant Pau, Autonomous University of Barcelona and Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas CIBERNED, Sant Antoni M Claret 167, 08025 Barcelona, Spain
    Parkinsons Dis 2010:930627. 2010
    ..To identify specific dysfunction of limbic structures in PD, patients with isolated apathy may have therapeutic and prognostic implications...
  3. doi request reprint Advanced Parkinson's disease: clinical characteristics and treatment. Part II
    J Kulisevsky
    Servicio de Neurologia, Hospital Sant Pau, Barcelona, España Electronic address
    Neurologia 28:558-83. 2013
    ..The different approaches which are now available include deep brain stimulation of the subthalamic nucleus or medial globus pallidus, subcutaneous infusion of apomorphine, and intestinal infusion of levodopa-carbidopa...
  4. ncbi request reprint [Advanced Parkinson's disease: clinical characteristics and treatment (part 1)]
    J Kulisevsky
    Servicio de Neurologia, Hospital Sant Pau, IIB Sant Pau, CIBERNED, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Neurologia 28:503-21. 2013
    ..Several authors refer to this stage of the disease as advanced Parkinson's disease...
  5. doi request reprint Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Spain
    Parkinsonism Relat Disord 19:812-7. 2013
    ..Little is known on the impact of cognitive impairment on instrumental activities of daily living (IADL) in pre-dementia stages of Parkinson's disease (PD)...
  6. doi request reprint Evaluation of doctor/patient satisfaction with the use of the Parkinson's Disease Dementia-Short-Screen (PDD-SS): a screening test for dementia in Parkinson's disease (DIFFUSION study)
    J Kulisevsky
    Unidad de Trastornos del Movimiento, Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Espana
    Neurologia 26:461-7. 2011
    ..A screening test for dementia in PD (Parkinson's Disease Dementia-Short Screen [PDD-SS]) has recently been validated. To assess the degree of satisfaction of patients and researchers through the use of PDD-SS in clinical practice...
  7. doi request reprint Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Institute of Biomedical Research Barcelona, Spain
    Eur Neurol 67:4-11. 2012
    ..Understanding the role of A(2A)-receptor antagonism in the pathophysiology of Parkinson's disease and DIMD has therapeutic implications...
  8. doi request reprint Motor changes during sertraline treatment in depressed patients with Parkinson's disease*
    J Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Eur J Neurol 15:953-9. 2008
    ..Whether selective serotonine re-uptake inhibitors increase parkinsonism or have clinically significant interactions with antiparkinsonian drugs is unresolved...
  9. ncbi request reprint Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Hospital de Sant Pau, Barcelona, Spain
    Mov Disord 24:1103-10. 2009
    ....
  10. ncbi request reprint Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model
    M Casas
    Departament de Psiquiatria, Institut de Recerca Sant Pau, Programa Sant Pau CITRAN y FISP, Universitat Autonoma de Barcelona, Unitat de Toxicomanies, Hospital de la Sta Creu i St Pau, Barcelona, Spain
    Eur Neuropsychopharmacol 9:515-21. 1999
    ....
  11. ncbi request reprint [Cognitive and functional decline in the stage previous to the diagnosis of Alzheimers disease]
    C García-Sánchez
    Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau Universidad Autónoma de Barcelona, Spain
    Neurologia 18:716-22. 2003
    ..The decline in the phase prior to diagnosis of Alzheimers disease (AD) is not well known, although this knowledge is necessary to evaluate the efficiency of new drugs that can influence in disease course prior to diagnosis...
  12. ncbi request reprint [Sustained attention in the preclinical phase of Alzheimer's disease]
    A Estévez-González
    Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Espana
    Rev Neurol 36:829-32. 2003
    ..Deterioration of attention in the preclinical phase of dementia of Alzheimer s type (DAT) is not very well known neither available studies are conclusive...
  13. doi request reprint Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances
    V Perez
    Laboratori de Neuropsicofarmacologia, Institut de Recerca de l Hospital de la Sta Creu i de Sant Pau, Avgda St Antoni M feminine Claret, 167, 08025, Barcelona, Spain
    J Neural Transm 116:1257-66. 2009
    ....
  14. ncbi request reprint SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study
    A M Catafau
    Nuclear Medicine Department, Hospital de Sant Pau, Pare Claret 167, 08025, Barcelona, Spain
    Psychiatry Res 106:151-60. 2001
    ..Cerebral perfusion SPECT is a useful tool to map cerebral activity changes induced by rTMS...
  15. ncbi request reprint Abnormalities of the acoustic startle reflex and reaction time in gilles de la tourette syndrome
    A Gironell
    Servei de Neurologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Neurophysiol 111:1366-71. 2000
    ..To study the startle reflex and the effect of the startle reflex stimulus over reaction time (start-react effect) in Gilles de la Tourette syndrome (GTS)...
  16. ncbi request reprint Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease
    J Kulisevsky
    Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Drugs Aging 16:365-79. 2000
    ..Meanwhile, such cognitive dissociation can be useful in refining the definition of the cognitive deficit in PD patients without dementia and emphasising the need to develop new and specific strategies for treatment...
  17. doi request reprint What contributes to driving ability in Parkinson's disease
    Esther Cubo
    Neurology Department, Hospital General Yague, Burgos, Spain
    Disabil Rehabil 32:374-8. 2010
    ..To determine the most significant clinical predictors that influence driving ability in Parkinson disease (PD)...
  18. ncbi request reprint Lack of prefrontal repetitive transcranial magnetic stimulation effects in time production processing
    A Gironell
    Cognitive and Movement Disorders Section, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Catalonia, Spain
    Eur J Neurol 12:891-6. 2005
    ..No significantly differences were observed in absolute error scores in time estimation task with any rTMS condition. This preliminary study does not support the role of the prefrontal lobe in time production processes...
  19. ncbi request reprint [Validation of the translation to Catalan and Spanish of cognitive evoked potential N400]
    A Gironell
    Servicio de Neurologia, Hospital de Sant Pau, Universidad Autonoma de Barcelona, Spain
    Neurologia 18:310-7. 2003
    ..The present study tries to validate the translation and adaptation of the English paradigm to the Catalan and Spanish languages...
  20. ncbi request reprint Unrecognized Tourette syndrome in adult patients referred for psychogenic tremor
    J Kulisevsky
    Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Arch Neurol 55:409-14. 1998
    ..The diagnosis of Tourette syndrome may be overlooked in patients with severe psychopathologic disorder but mild motor manifestations of Tourette syndrome...
  21. ncbi request reprint Motor circuitry re-organization after pallidotomy in Parkinson disease: a neurophysiological study of the bereitschaftspotential, contingent negative variation, and N30
    A Gironell
    Servei de Neurologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Catalonia, Spain
    J Clin Neurophysiol 19:553-61. 2002
    ..These results suggest that neurophysiological changes after pallidotomy are mainly in the last stages of movement preparation and execution...
  22. doi request reprint Impulse control disorders and dopaminergic treatments in Parkinson's disease
    C Villa
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Institut d Investigacions Biosanitàries, Sant Pau IIB Sant Pau, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas CIBERNED, C Mas Casanovas 90, 08025 Barcelona, Spain
    Rev Neurol (Paris) 167:827-32. 2011
    ..ICDs in PD may greatly affect patients and caregivers quality of life, stressing the importance of their screening. Management strategies include a careful use of dopaminergic therapy using the lowest effective doses...
  23. ncbi request reprint Mania following deep brain stimulation for Parkinson's disease
    J Kulisevsky
    Movement Disorders Unit, Department of Neurology, Functional Neurosurgery Program for Movement Disorders, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Neurology 59:1421-4. 2002
    ....
  24. doi request reprint Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes
    Núria Setó-Salvia
    Memory Unit, Neurology Department, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Sant Antoni M Claret 167, 08025 Barcelona, Spain
    Arch Neurol 68:359-64. 2011
    ..Dementia in Parkinson disease (PD) causes nursing home placement, caregiver distress, higher health care burden, and increased mortality...
  25. ncbi request reprint [Pramipexole and Parkinson's disease, an update]
    M Martinez-Corral
    Unidad de Trastornos del Movimiento, Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau, Barcelona
    Rev Neurol 46:49-52. 2008
    ..Further studies need to be conducted to help define the long-term effects of dopaminergic agonists on the progress of the disease and also to show the differences between non-ergotic agonists in clinical practice...
  26. doi request reprint Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study
    F Valldeoriola
    Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Neurol Neurosurg Psychiatry 81:65-9. 2010
    ..Some clinical aspects of GPi stimulation in primary dystonia still remain controversial such as the influence of disease duration or age at onset in determining the postoperative clinical outcome...
  27. ncbi request reprint [Postural tremor: clinical and neurophysiological study in a consecutive series of 300 patients]
    A Gironell
    Secció De Trastorns del Moviment, Servei de Neurologia, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Spain
    Med Clin (Barc) 117:601-5. 2001
    ..There are few studies analysing the clinical and neurophysiological characteristics of postural tremor in Spain...
  28. doi request reprint Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease
    Esther Cubo
    Neurology Department, Hospital General Yague, Burgos, Spain
    Mov Disord 25:70-5. 2010
    ..This study was designed to evaluate the predominant laterality of motor symptoms and its relationship with cognition and other NMS in idiopathic PD...
  29. ncbi request reprint Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders
    J Kulisevsky
    Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Mov Disord 16:1098-104. 2001
    ..Abnormalities of other brain structures (e.g., amygdala, brainstem nuclei) may account for the significantly higher anxiety scores differentiating GTS from HD patients...
  30. doi request reprint The Glass scale: a simple tool to determine severity in essential tremor
    Alexandre Gironell
    Movement Disorders Unit, Department of Neurology, Hospital de Sant Pau, Av Sant Antoni Maria Claret 167, 08025 Barcelona, Catalonia, Spain
    Parkinsonism Relat Disord 16:412-4. 2010
    ..The method for measuring disease severity in essential tremor (ET) is not consistent among neurologists in routine clinical practice...
  31. ncbi request reprint Short-lasting episodes of prosopagnosia in Parkinson's disease
    C Villa-Bonomo
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Universitat Autonoma de Barcelona, Institut d Investigacions Biosanitàries, Sant Pau, and Centro de Investigación Biomédica en Red sobre Enfermedades neurodegenerativas, C Mas Casanovas, 90, Barcelona 08025, Spain
    Parkinsonism Relat Disord 19:375-7. 2013
    ..Prosopagnosia, the selective inability to recognize known faces, has been described in Alzheimer's disease and fronto-temporal dementia but is not expected to occur in Parkinson's disease (PD)...
  32. ncbi request reprint Effects of repetitive transcranial magnetic stimulation on memory subtypes: a controlled study
    L Rami
    Department of Neurology, Hospital de la Santa Creu i Sant Pau, Avenue Sant Antoni Maria Claret 167, 08025 Barcelona, Catalonia, Spain
    Neuropsychologia 41:1877-83. 2003
    ..009). No significant differences were found in the other memory subtype tasks analysed during the different rTMS conditions. These findings provide evidence for the significant role of the left DLPFC in episodic verbal memory processes...
  33. doi request reprint Motor and mental dysfunction in mother-daughter transmitted FXTAS
    L Rodriguez-Revenga
    CIBER de Enfermedades Raras, Barcelona, Spain
    Neurology 75:1370-6. 2010
    ..Herein 2 fragile X syndrome families with a mother-daughter FXTAS transmission are described in detail in order to shed more light on the female FXTAS phenotype...
  34. doi request reprint PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Mov Disord 25:440-6. 2010
    ..The PDD-SS appears as the first BST for diagnosing PDD, displays an excellent diagnostic accuracy, and takes 5 to 7 minutes to be administered...
  35. doi request reprint Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Mov Disord 23:998-1005. 2008
    ..Performance on the PD-CRS showed that PDD is characterized by the addition of cortical dysfunction upon a predominant and progressive fronto-subcortical impairment...
  36. ncbi request reprint Controlled study of decision-making and cognitive impairment in Parkinson's disease
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Mov Disord 22:1430-5. 2007
    ..Although impaired decision-making appears unrelated to executive dysfunction, patients with the better cognitive status appears more prone to assume risky behaviors...
  37. ncbi request reprint [Dementia with Lewy bodies and Alzheimer's disease: differential diagnosis by cardiac sympathetic innervation MIBG imaging]
    M Estorch
    Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Espana
    Rev Esp Med Nucl 25:229-35. 2006
    ....
  38. ncbi request reprint [Initial treatment of Parkinson's disease]
    J Kulisevsky
    , Hospital de la Santa Creu i Sant Pau, Barcelona,
    Rev Neurol 25:S163-9. 1997
    ..Selegiline, a MAOB inhibitor with a possible neuroprotective effect, should also be considered as initial option for Parkinson's disease...
  39. ncbi request reprint [Weight gain after functional surgery for Parkinsons disease]
    A Gironell
    Secció De Trastorns del Moviment, Servei de Neurologia, Hospital de Sant Pau, Universitat Autonoma de Barcelona, Spain
    Neurologia 17:310-6. 2002
    ..The origin of weight gain after functional surgery for Parkinson's disease (PD) is incompletely known. We have done a prospective study to determine the possible causes of weight gain after pallidal and subthalamic surgery...
  40. doi request reprint Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease
    Gisela Llebaria
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona and CIBERNED Centro de Investigaciones Biomédicas en Red Enfermedades Neurodegenerativas, Barcelona, Spain
    Mov Disord 23:1546-50. 2008
    ..The MDRS has an excellent discriminant ability to diagnose dementia in PD and provides an objective measure to distinguish PD-ND from PDD...
  41. doi request reprint Levodopa and executive performance in Parkinson's disease: a randomized study
    Berta Pascual-Sedano
    Department of Neurology Movement Disorders Unit and CIBERNED, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
    J Int Neuropsychol Soc 14:832-41. 2008
    ..A slower rise in LD levels appears to have a more favorable impact on more difficult working memory tests. These results require replication to determine their generalization...
  42. ncbi request reprint Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario
    M J Barbanoj
    Centre d Investigacio de Medicaments, Institut de Recerca, Servei de Faramacologia Clínica, HSCSP, Departament de Farmacologia i Terapèutica UAB, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 24:139-44. 2002
    ..Much work is still need to develop fully the potentials that pharmaco-EEG together with pharmacokinetic-pharmacodynamic modeling could bring to therapeutics in neuroscience...
  43. ncbi request reprint [Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?]
    Javier Pagonabarraga
    Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Espana
    Rev Neurol 58:25-34. 2014
    ....
  44. ncbi request reprint Alien hand sign after a right parietal infarction
    J Marti-Fabregas
    Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cerebrovasc Dis 10:70-2. 2000
    ..This combination, that can meet the criteria for the 'alien hand syndrome', is rarely seen after acute lesions sparing the corpus callosum and the mesial frontal areas...
  45. ncbi request reprint [Extrapyramidal effects of antipsychotic drugs]
    J Kulisevsky
    Sección de Transtornos del Movimiento, Servicio de Neurologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Sapin
    Neurologia 18:262-8. 2003
    ..This article reviews these drugs, their pharmacological characteristics as well as the phenomenology of the extrapyramidal syndromes ans treatment of the EPS recommended...
  46. ncbi request reprint Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats
    M Casas
    Institut de Recerca Sant Pau, Departament de Psiquiatria, Universitat Autonoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Spain
    Eur J Pharmacol 366:1-11. 1999
    ..The results are interpreted in terms of the possible interactions between dopamine, adenosine and acetylcholine neurotransmitter systems within the basal ganglia circuitry involved in motor behavior...
  47. ncbi request reprint Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. A controlled comparative study
    Alexandre Gironell
    Cognitive and Movement Disorders Section, Dept of Neurology, Sant Pau Hospital Autonomous University of Barcelona, Barcelona, Catalonia, Spain
    J Neurol 250:917-23. 2003
    ..005). This controlled comparative study suggests that neither unilateral pallidotomy nor bilateral STN-DBS have global adverse cognitive consequences, but bilateral STN-DBS may cause a selective decrease in verbal fluency...
  48. ncbi request reprint Semantic knowledge of famous people in mild cognitive impairment and progression to Alzheimer's disease
    Armando Estévez-González
    Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
    Dement Geriatr Cogn Disord 17:188-95. 2004
    ..A neuropsychological task of semantic knowledge of famous people may be useful in the early diagnosis of Alzheimer's disease...
  49. doi request reprint Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia
    Jaime Kulisevsky
    Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Mov Disord 23:1889-96. 2008
    ..Apathy emerged as an independent construct in PD-ND, indicating the need to address specific therapeutical approaches targeted toward this particular symptom...
  50. ncbi request reprint A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia
    Javier Pagonabarraga
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, CIBERNED Barcelona, Spain
    Mov Disord 23:443-8. 2008
    ..DMS is a neuropsychiatric feature associated with PDD. Greater impairment in language and memory in PDD with DMS suggests a prominent role of the temporal cortex in the genesis of DMS in PDD...
  51. ncbi request reprint Transcranial magnetic stimulation of the cerebellum in essential tremor: a controlled study
    Alexandre Gironell
    Servei de Neurologia, Hospital de Sant Pau, Av Sant Antoni Ma Claret 167, 08025 Barcelona, Catalonia, Spain
    Arch Neurol 59:413-7. 2002
    ....
  52. ncbi request reprint A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease
    Jaime Kulisevsky
    Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Clin Neuropharmacol 25:25-31. 2002
    ..During this exploratory study, the effects of theophylline were not strong enough to potentiate clearly the antiparkinsonian action of levodopa or to increase ON time in patients with advanced PD...
  53. ncbi request reprint Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis
    Jose Luis R Martin
    Iberoamerican Cochrane Centre, Hospital de la Santa Crue i Sant Pau, Barcelona, Spain
    Br J Psychiatry 182:480-91. 2003
    ..Repetitive transcranial magnetic stimulation (rTMS) may be useful in the treatment of depression but results from trials have been inconclusive to date...
  54. ncbi request reprint Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: a prospective study
    Alexandre Gironell
    Department of Neurology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Catalonia, Spain
    Mov Disord 18:1273-9. 2003
    ..The three neurophysiological tests investigated provided sensitive and specific measures with predictor value in early stages of atypical parkinsonian syndrome...
  55. ncbi request reprint Hallucinations and sleep disturbances in Parkinson's disease
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain
    Neurology 63:S28-30. 2004
    ..In some patients, VHs may represent intrusion of REM sleep-related imagery into wakefulness. Improving REM sleep abnormalities in PD (e.g., stimulants, anticholinesterase inhibitors) is one strategy now being tested to improve VHs in PD...
  56. ncbi request reprint Usefulness of p300 in subjective memory complaints: a prospective study
    Alexandre Gironell
    Cognitive Disorders Section, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
    J Clin Neurophysiol 22:279-84. 2005
    ..9% and a specificity of 76.9%; the odds ratio was 3.75 (95% confidence interval, 1.23-11.41). Findings from the present study suggest that assessment of evoked related potentials may contribute to the early detection of DAT...
  57. ncbi request reprint Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Autonomous University of Barcelona, Barcelona, Spain
    Mov Disord 22:62-7. 2007
    ..Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement...
  58. doi request reprint Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity
    Jaime Kulisevsky
    Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Sant Antoni Maria Claret 167, Barcelona 08025, Spain
    J Neurol 256:816-9. 2009
    ..This case suggests that changes in creativity in PD seem to be related to dopaminergic imbalance in the limbic system...
  59. ncbi request reprint Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening
    Jordi Clarimon
    Memory Unit, Alzheimer s Laboratory, and Centro de Investigación Biomédica en Red CIBERNED, Neurology Department, Sant Pau Hospital, Barcelona, Spain
    Mov Disord 23:518-23. 2008
    ....
  60. doi request reprint Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials
    Jaime Kulisevsky
    Unit of Movement Disorders, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Drug Saf 33:147-61. 2010
    ..Dopamine agonists have a well established role in the treatment of Parkinson's disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication...